Literature DB >> 25838121

Evaluating HIV prevention strategies for populations in key affected groups: the example of Cabo Verde.

João Filipe G Monteiro1, Sandro Galea, Timothy Flanigan, Maria de Lourdes Monteiro, Samuel R Friedman, Brandon D L Marshall.   

Abstract

OBJECTIVES: We used an individual-based model to evaluate the effects of hypothetical prevention interventions on HIV incidence trajectories in a concentrated, mixed epidemic setting from 2011 to 2021, and using Cabo Verde as an example.
METHODS: Simulations were conducted to evaluate the extent to which early HIV treatment and optimization of care, HIV testing, condom distribution, and substance abuse treatment could eliminate new infections (i.e., reduce incidence to less than 10 cases per 10,000 person-years) among non-drug users, female sex workers (FSW), and people who use drugs (PWUD).
RESULTS: Scaling up all four interventions resulted in the largest decreases in HIV, with estimates ranging from 1.4 (95 % CI 1.36-1.44) per 10,000 person-years among non-drug users to 8.2 (95 % CI 7.8-8.6) per 10,000 person-years among PWUD in 2021. Intervention scenarios prioritizing FWS and PWUD also resulted in HIV incidence estimates at or below 10 per 10,000 person-years by 2021 for all population sub-groups.
CONCLUSIONS: Our results suggest that scaling up multiple interventions among entire population is necessary to achieve elimination. However, prioritizing key populations with this combination prevention strategy may also result in a substantial decrease in total incidence.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25838121      PMCID: PMC4545645          DOI: 10.1007/s00038-015-0676-9

Source DB:  PubMed          Journal:  Int J Public Health        ISSN: 1661-8556            Impact factor:   3.380


  29 in total

1.  [HIV seroprevalence among drug users in Togo].

Authors:  Didier K Ekouevi; Patrick A Coffie; Mounerou Salou; Benjamin G Kariyiare; Anoumou C Dagnra; Boris Tchounga; Mireille Prince-Davi; Renaud Becquet; Vincent P Pitche
Journal:  Sante Publique       Date:  2013 Jul-Aug       Impact factor: 0.203

Review 2.  HIV prevention transformed: the new prevention research agenda.

Authors:  Nancy S Padian; Sandra I McCoy; Salim S Abdool Karim; Nina Hasen; Julia Kim; Michael Bartos; Elly Katabira; Stefano M Bertozzi; Bernhard Schwartländer; Myron S Cohen
Journal:  Lancet       Date:  2011-07-16       Impact factor: 79.321

3.  Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda.

Authors:  Maria J Wawer; Ronald H Gray; Nelson K Sewankambo; David Serwadda; Xianbin Li; Oliver Laeyendecker; Noah Kiwanuka; Godfrey Kigozi; Mohammed Kiddugavu; Thomas Lutalo; Fred Nalugoda; Fred Wabwire-Mangen; Mary P Meehan; Thomas C Quinn
Journal:  J Infect Dis       Date:  2005-03-30       Impact factor: 5.226

4.  A novel combination HIV prevention strategy: post-exposure prophylaxis with contingency management for substance abuse treatment among methamphetamine-using men who have sex with men.

Authors:  Raphael J Landovitz; Jesse B Fletcher; Galina Inzhakova; Jordan E Lake; Steven Shoptaw; Cathy J Reback
Journal:  AIDS Patient Care STDS       Date:  2012-06       Impact factor: 5.078

5.  Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study.

Authors:  Julio S G Montaner; Viviane D Lima; Rolando Barrios; Benita Yip; Evan Wood; Thomas Kerr; Kate Shannon; P Richard Harrigan; Robert S Hogg; Patricia Daly; Perry Kendall
Journal:  Lancet       Date:  2010-07-16       Impact factor: 79.321

6.  Norms, social networks, and HIV-related risk behaviors among urban disadvantaged drug users.

Authors:  Carl A Latkin; Valerie Forman; Amy Knowlton; Susan Sherman
Journal:  Soc Sci Med       Date:  2003-02       Impact factor: 4.634

7.  HIV and STI prevalence among female sex workers in Côte d'Ivoire: why targeted prevention programs should be continued and strengthened.

Authors:  Bea Vuylsteke; Gisèle Semdé; Lazare Sika; Tania Crucitti; Virginie Ettiègne Traoré; Anne Buvé; Marie Laga
Journal:  PLoS One       Date:  2012-03-05       Impact factor: 3.240

8.  Differences between HIV-Infected men and women in antiretroviral therapy outcomes - six African countries, 2004-2012.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-11-29       Impact factor: 17.586

9.  Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa.

Authors:  Sabina S Alistar; Philip M Grant; Eran Bendavid
Journal:  BMC Med       Date:  2014-03-17       Impact factor: 11.150

10.  Barriers and facilitators to pre-exposure prophylaxis (PrEP) eligibility screening and ongoing HIV testing among target populations in Bondo and Rarieda, Kenya: results of a consultation with community stakeholders.

Authors:  Natasha Mack; Jacob Odhiambo; Christina M Wong; Kawango Agot
Journal:  BMC Health Serv Res       Date:  2014-05-21       Impact factor: 2.655

View more
  4 in total

1.  Understanding the effects of different HIV transmission models in individual-based microsimulation of HIV epidemic dynamics in people who inject drugs.

Authors:  J F G Monteiro; D J Escudero; C Weinreb; T Flanigan; S Galea; S R Friedman; B D L Marshall
Journal:  Epidemiol Infect       Date:  2016-01-12       Impact factor: 2.451

2.  Using medical examiner case narratives to improve opioid overdose surveillance.

Authors:  Emily Hurstak; Christopher Rowe; Caitlin Turner; Emily Behar; Rachel Cabugao; Nikolas P Lemos; Catherine Burke; Phillip Coffin
Journal:  Int J Drug Policy       Date:  2018-01-30

3.  The Interaction of Risk Network Structures and Virus Natural History in the Non-spreading of HIV Among People Who Inject Drugs in the Early Stages of the Epidemic.

Authors:  Kirk Dombrowski; Bilal Khan; Patrick Habecker; Holly Hagan; Samuel R Friedman; Mohamed Saad
Journal:  AIDS Behav       Date:  2017-04

Review 4.  Evolving HIV epidemics: the urgent need to refocus on populations with risk.

Authors:  Tim Brown; Wiwat Peerapatanapokin
Journal:  Curr Opin HIV AIDS       Date:  2019-09       Impact factor: 4.283

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.